Sandy Cove Advisors’s United Therapeutics UTHR Stock Holding History

Sandy Cove Advisors’s Portfolio UTHR Stock Details UTHR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q2	–	Sell	-325	Closed	-$58K	–	369
2022 Q1	$58K	Buy	+325	New	+$61.9K	0.05%	180

Other funds holding UTHR

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return

APM

Avidity Partners Management Dallas, Texas $624M AUM 250.2% 1-Year Est. Return

Janus Henderson Group London $209B AUM 37.72% 1-Year Est. Return

Sandy Cove Advisors's UTHR Position: Q2 2022 in Review

Sandy Cove Advisors sold out of United Therapeutics (UTHR) in Q2 2022, closing a stake of 325 shares — an estimated $58K sold.

Sandy Cove Advisors first reported a position in UTHR in Q1 2022 and held it in 1 quarter. The position peaked at $58K in Q1 2022. 472 funds tracked by Wall St. Rank hold UTHR as of Q2 2022.

Sandy Cove Advisors reported no remaining United Therapeutics position as of Q2 2022 after selling out during the quarter.
Sandy Cove Advisors sold 325 United Therapeutics shares in Q2 2022, an estimated $58K.
Sandy Cove Advisors first reported a position in United Therapeutics in Q1 2022 and held it in 1 quarter.
Sandy Cove Advisors's United Therapeutics position peaked at $58K in Q1 2022.
472 funds tracked by Wall St. Rank held United Therapeutics as of Q2 2022.

Based on Sandy Cove Advisors's 13F filing for Q2 2022, filed 11 Aug 2022.